课题基金 / 基金详情

PHARMACOLOGY OF COGNITION IN SCHIZOTYPAL PERSONALITY

PHARMACOLOGY OF COGNITION IN SCHIZOTYPAL PERSONALITY
精神分裂型人格认知的药理学
批准号:
2675537
负责人:
Larry J Siever
金额:
$23.0万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-04-01 至 2002-03-31

项目摘要

项目成果

Larry J Siever的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from applicant's abstract): The proposed studies aim to define the cognitive impairment associated with SPD and to evaluate the effect of an acute pharmacologic intervention with amphetamine on the cognitive function of SPD patients. SPD patients share important phenomenologic, genetic, and neurobiologic commonalities with chronic schizophrenia, particularly a core cognitive/attentional impairment. Their study, however, minimized the multiple confounding artifacts associated with the study of schizophrenic patients and offers an opportunity to potentially disentangle the multiple pathophysiologic mechanisms implicated in the schizophrenic disorders. Like schizophrenic patients, SPD patients demonstrate impaired performance on tests of visuospatial working memory, verbal learning, and sustained attention compared to other personality disorder patients and normal controls in the investigator's studies to date. Preliminary data suggests amphetamine can ameliorate these cognitive impairments in SPD patients. This study is designed to test the primary hypotheses that SPD patients will show cognitive impairment in both verbal and visuospatial domains respectively in three areas of cognitive function compared to other non-odd cluster personality disorder (OPD) patients and normal controls: 1) working memory (Paced Auditory Serial Addition Test (PASAT) and DOT tests) 2) learning and memory (serial word list learning and Wechsler Memory Scale Visual Reproduction (WMS-VR)) and 3) sustained attention (Continuous Performance Task (CPT-IP), digits and shapes. SPD patients will be evaluated on these cognitive tasks during placebo and amphetamine to test the hypothesis that 4) they will demonstrate significant improvement in performance in these three domains after administration of 30 mgs. of oral amphetamine and 5) there will be a significant diagnosis by drug interaction for the performance of these cognitive tasks with the SPD group demonstrating significantly improved performance compared to the OPD or the normal comparison group after amphetamine compared to placebo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A D1 Agonist for Working Memory Enhancement in the Schizophrenia Spectrum
White Matter Abnormalities in the Schizophrenia Spectrum
  • 批准号:
    8698390
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    Larry J Siever
  • 依托单位:
White Matter Abnormalities in the Schizophrenia Spectrum
  • 批准号:
    8444260
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    Larry J Siever
  • 依托单位:
White Matter Abnormalities in the Schizophrenia Spectrum
  • 批准号:
    8246551
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    Larry J Siever
  • 依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    郑巧
  • 依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    陈立达
  • 依托单位: